Scott A I, Perini A F, Shering P A, Whalley L J
University Department of Psychiatry, Royal Edinburgh Hospital, UK.
Eur J Clin Pharmacol. 1991;40(2):127-9. doi: 10.1007/BF00280065.
The antidepressant efficacy and adverse-effects of rolipram (a dialkoxyphenyl-2-pyrrolidone) were compared to those of amitriptyline in the treatment of depressive illness requiring hospital admission in a double-blind study. Fifty patients meeting DSM-III criteria for Major Depression whose scores on the Hamilton Rating Scale for Depression (HRSD) remained above 17 after 5 to 7 days on placebo were randomly allocated to either treatment. The rate of recovery in those patients treated by amitriptyline was substantially greater than in those patients treated by rolipram. Twice as many patients dropped out of treatment by rolipram because of lack of efficacy or adverse-effects compared with patients treated by amitriptyline. Rolipram produced fewer adverse-effects attributable to cholinergic blockade, but more nausea. We conclude that amitriptyline is more effective than rolipram in the treatment of depressed hospital in-patients.
在一项双盲研究中，比较了咯利普兰（一种二烷氧基苯基-2-吡咯烷酮）与阿米替林治疗需住院的抑郁症的抗抑郁疗效及不良反应。50例符合DSM-III重度抑郁症标准、在服用安慰剂5至7天后汉密尔顿抑郁量表（HRSD）评分仍高于17分的患者被随机分配接受两种治疗。接受阿米替林治疗的患者的康复率显著高于接受咯利普兰治疗的患者。与接受阿米替林治疗的患者相比，因疗效不佳或不良反应而退出咯利普兰治疗的患者人数是其两倍。咯利普兰引起的胆碱能阻滞不良反应较少，但恶心更多。我们得出结论，在治疗住院抑郁症患者方面，阿米替林比咯利普兰更有效。
